These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11583479)

  • 21. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity.
    Tacconelli S; Capone ML; Sciulli MG; Ricciotti E; Patrignani P
    Curr Med Res Opin; 2002; 18(8):503-11. PubMed ID: 12564662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis.
    Schwartz JI; Agrawal NG; Wong PH; Miller J; Bachmann K; Marbury T; Hoelscher D; Cavanaugh PF; Gottesdiener K
    J Clin Pharmacol; 2009 Oct; 49(10):1202-9. PubMed ID: 19783714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma.
    Werner U; Werner D; Hinz B; Lambrecht C; Brune K
    Biomed Chromatogr; 2005 Mar; 19(2):113-8. PubMed ID: 15473012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
    Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret JP; Friesen RW; Gordon R; Greig G; Guay J; Mancini J; Ouellet M; Wong E; Xu L; Boyce S; Visco D; Girard Y; Prasit P; Zamboni R; Rodger IW; Gresser M; Ford-Hutchinson AW; Young RN; Chan CC
    J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor.
    Kassahun K; McIntosh IS; Shou M; Walsh DJ; Rodeheffer C; Slaughter DE; Geer LA; Halpin RA; Agrawal N; Rodrigues AD
    Drug Metab Dispos; 2001 Jun; 29(6):813-20. PubMed ID: 11353749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).
    Chauret N; Yergey JA; Brideau C; Friesen RW; Mancini J; Riendeau D; Silva J; Styhler A; Trimble LA; Nicoll-Griffith DA
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1059-62. PubMed ID: 11327589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
    Matsumoto AK; Melian A; Mandel DR; McIlwain HH; Borenstein D; Zhao PL; Lines CR; Gertz BJ; Curtis S;
    J Rheumatol; 2002 Aug; 29(8):1623-30. PubMed ID: 12180720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
    El Miedany Y; Youssef S; Ahmed I; El Gaafary M
    Ann Allergy Asthma Immunol; 2006 Jul; 97(1):105-9. PubMed ID: 16892790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial.
    Malmstrom K; Kotey P; Cichanowitz N; Daniels S; Desjardins PJ
    Gynecol Obstet Invest; 2003; 56(2):65-9. PubMed ID: 12900528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers.
    Shohag MH; Islam MS; Ahmed MU; Joti JJ; Islam MS; Hasanuzzaman M; Hasnat A
    Arzneimittelforschung; 2011; 61(11):617-21. PubMed ID: 22232850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs.
    Nettis E; Colanardi MC; Ferrannini A; Vacca A; Tursi A
    Ann Allergy Asthma Immunol; 2005 Nov; 95(5):438-42. PubMed ID: 16312166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial.
    Bickham K; Kivitz AJ; Mehta A; Frontera N; Shah S; Stryszak P; Popmihajlov Z; Peloso PM
    BMC Musculoskelet Disord; 2016 Aug; 17():331. PubMed ID: 27502582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of etoricoxib in patients with hepatic impairment.
    Agrawal NG; Rose MJ; Matthews CZ; Woolf EJ; Porras AG; Geer LA; Larson PJ; Cote J; Dilzer SC; Lasseter KC; Alam I; Petty KJ; Gottesdiener KM
    J Clin Pharmacol; 2003 Oct; 43(10):1136-48. PubMed ID: 14517196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.
    Felden L; Walter C; Angioni C; Schreiber Y; von Hentig N; Ferreiros N; Geisslinger G; Lötsch J
    Pharm Res; 2014 Jul; 31(7):1813-22. PubMed ID: 24469906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis.
    Greenwald M; Peloso PM; Mandel D; Soto O; Mehta A; Frontera N; Boice JA; Zhan XJ; Curtis SP
    Curr Med Res Opin; 2011 Oct; 27(10):2033-42. PubMed ID: 21905970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etoricoxib.
    Matsumoto AK; Cavanaugh PF
    Drugs Today (Barc); 2004 May; 40(5):395-414. PubMed ID: 15319795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
    van der Heijde D; Baraf HS; Ramos-Remus C; Calin A; Weaver AL; Schiff M; James M; Markind JE; Reicin AS; Melian A; Dougados M
    Arthritis Rheum; 2005 Apr; 52(4):1205-15. PubMed ID: 15818702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
    Krum H; Curtis SP; Kaur A; Wang H; Smugar SS; Weir MR; Laine L; Brater DC; Cannon CP
    Eur J Heart Fail; 2009 Jun; 11(6):542-50. PubMed ID: 19380329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Another selective COX-2 inhibitor: more questions than answers?
    Day R
    J Rheumatol; 2002 Aug; 29(8):1581-2. PubMed ID: 12180711
    [No Abstract]   [Full Text] [Related]  

  • 40. Isolation and structural characterization of the photolysis products of etoricoxib.
    Matthews CZ; Subramanian R; Woolf EJ; Foster N; Matuszewski BK
    Pharmazie; 2004 Dec; 59(12):913-9. PubMed ID: 15638077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.